Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
IDH1 mutant gliomas are thought to have distinct metabolic characteristics, including a blunted response to hypoxia and lower glycolytic flux. We hypothesized non-invasive quantification of abnormal metabolic behavior in human IDH1 mutant gliomas could be performed using a new pH- and oxygen-sensitive molecular MRI technique. Simultaneous pH- and oxygen-sensitive MRI was obtained at 3T using amine CEST-SAGE-EPI. The pH-dependent measure of MTRasym at 3ppm and oxygen-sensitive measure of R2' were quantified in 90 patients with gliomas. Additionally, stereotactic, image-guided biopsies were performed in 20 patients for a total of 52 samples. The association between imaging measurements and HIF1α expression were identified using Pearson correlation analysis. IDH1 mutant gliomas exhibited significantly lower MTRasym at 3ppm, R2', and MTRasymxR2' (P=0.007, P=0.003, and P=0.001, respectively). MTRasymxR2' could identify IDH1 mutant gliomas with a high sensitivity (81.0%) and specificity (81.3%). HIF1α was positively correlated with MTRasym at 3ppm, R2' and MTRasymxR2' in IDH1 wildtype (r=0.610, P=0.003; r=0.667, P=0.008; r=0.635, P=0.006), but only MTRasymxR2' in IDH1 mutant gliomas (r=0.727, P=0.039). IDH1 mutant gliomas have distinct metabolic and microenvironment characteristics compared to wild type gliomas. An imaging biomarker combining tumor acidity and hypoxia (MTRasymxR2') can differentiate IDH1 mutation status and is correlated with tumor acidity and hypoxia.